Achieve Life Sciences is a biopharmaceutical company that develops and commercializes therapies that address treatment resistance in cancer patients. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. The Company is also working on cytisine-based therapies as a widely available treatment option for nicotine addiction.